Propylisopropyltryptamine

Propylisopropyltryptamine
Clinical data
Other namesPiPT; N-Propyl-N-isopropyltryptamine
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • none
Identifiers
IUPAC name
  • [2-(1H-indol-3-yl)ethyl]-N-propyl-N-isopropylamine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H24N2
Molar mass244.382 g·mol−1
3D model (JSmol)
SMILES
  • CC(C)N(CCC)CCc2c[nH]c1ccccc12
InChI
  • InChI=1S/C16H24N2/c1-4-10-18(13(2)3)11-9-14-12-17-16-8-6-5-7-15(14)16/h5-8,12-13,17H,4,9-11H2,1-3H3 checkY
  • Key:OFXPLOPRCQJJFP-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Propylisopropyltryptamine (PiPT), also known as N-propyl-N-isopropyltryptamine, is a psychedelic drug of the tryptamine family. It reportedly produces hallucinogenic effects that resemble those of other related dialkyl tryptamine derivatives,[1] although PiPT is reportedly relatively weak and short-lasting. It has been sold as a designer drug, first being identified in 2021 in British Columbia, Canada.[2]

Use and effects

According to Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved), PiPT had not yet been evaluated.[3]

Interactions

Chemistry

PiPT is short for N-propyl-N-isopropyltryptamine. PiPT is a tryptamine, which all belong to a larger family of compounds known as indolethylamines

Analogues

Analogues of PiPT include methylisopropyltryptamine (MiPT), ethylisopropyltryptamine (EiPT), diisopropyltryptamine (DiPT), and dipropyltryptamine (DPT), among others.[3]

Society and culture

United States

PiPT is unscheduled and uncontrolled in the United States.

See also

References

  1. ↑ Catalani V, Corkery JM, Guirguis A, Napoletano F, Arillotta D, Zangani C, Vento A, Schifano F (August 2021). "Psychonauts' psychedelics: A systematic, multilingual, web-crawling exercise". European Neuropsychopharmacology. 49: 69–92. doi:10.1016/j.euroneuro.2021.03.006. hdl:2299/24309. PMID 33857740. S2CID 233206904.
  2. ↑ Knill A, Tobias S, Matthews J, Ti L (June 2022). A Report on British Columbia’s Unregulated Drug Supply. Drug checking trends across British Columbia, January to December 2021 (PDF). British Columbia Centre on Substance Use (Report).
  3. 1 2 Shulgin, Alexander; Shulgin, Ann (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.
This article is issued from WikiProjectMed. The text is available under Creative Commons Attribution-ShareAlike License unless otherwise noted. Additional terms may apply for the media files.